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81Introduction
The art and science of radiopharmaceutical production is evolv-
ing in a number of ways. First, the environment surrounding
production of radiopharmaceuticals is becoming much more
regulated, with production of clinical doses according to Current
Good Manufacturing Practice (cGMP) becoming standard in
most countries. For example, the U.S. FDA approved a set of
regulations describing production of positron emission tomography
(PET) radiopharmaceuticals according to cGMP, outlined in the Code
of Federal Regulations (21CFR212), which are set to become effec-
tive in December 2011. Second, in part to address these new regu-
latory demands, the ﬁeld of radiochemistry is increasingly migrating
toward the use of commercially available automated synthesis
modules for production of clinical radiopharmaceutical doses
(although manual synthetic techniques can also be conducted in
compliance with cGMP). The advantages of using automated
synthesis modules over more traditional ‘manual’ synthetic
approaches include (i) automation of radiochemical syntheses pro-
viding robust, repeatable processes; (ii) the ability to handle multi-
ple Curies of radioactivity safely enabling PET Centers to produce
and distribute hundreds of doses daily; (iii) facilitated regulatory
compliance through manufacturer installation qualiﬁcation/
operational qualiﬁcation/performance qualiﬁcation and scheduled
maintenance protocols performed on synthesismodules by trained
service engineers; and (iv) improved radiation safety through
reduction (or elimination) of manual operations. However, in
addition to these advantages, the move toward exclusive use of
automated synthesis modules also has associated challenges. TheJ. Label Compd. Radiopharm 2011, 54 819–838most signiﬁcant is the issue of re-conﬁguring synthesis modules
for production of radiopharmaceuticals that require non-conventional
radiochemistry strategies, while maintaining full automation.
At the University of Michigan, carbon-11 labeled radiopharma-
ceuticals are prepared using General Electric Medical Systems
(GEMS) TracerLab FXC-Pro automated synthesis modules. As the
demand for doses of different carbon-11 labeled radiopharma-
ceuticals prepared for clinical research, many of which are
prepared using complex radiochemical techniques, continues
to increase, we1–4 and others5–15 have had to address the issue
of frequent synthesis module reconﬁguration. For example, we
recently described preparation of multiple carbon-11 labeled
radiopharmaceuticals using a single TracerLab FXC-Pro that
removed the need to open the hot-cell door between syntheses,1
and in Part 1 of this series of articles, we reported simple modiﬁca-
tions to a TracerLab FXFN that enable fully automated production
of a range of ﬂuorine-18 labeled radiopharmaceuticals.16 In Part 2
of this series, we report conﬁgurational changes to a TracerLab
FXC-Pro that allow for straightforward switching between produc-
tion of [11C]-labeled radiopharmaceuticals using routine carbon-11
methylation chemistry, and those prepared using less trivial radio-
chemical techniques (e.g., alkylation of [11C]CO2 with GrignardCopyright © 2011 John Wiley & Sons, Ltd.
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820reagents). Proof-of-concept is demonstrated through the simple,
fully automated production of 12 different [11C]-labeled radiophar-
maceuticals (Figures 1 and 2) using a single TracerLab FXC-Pro
(Figure 3).Figure 2. Carbon-11 labeled radiopharmaceuticals (continuation).Automated radiopharmaceutical production
using a Tracerlab FXC-Pro
Introduction
General modiﬁcations to the Tracerlab FXC-Pro
The Tracerlab FXC-Pro synthesis module is installed ‘out-of-the-
box’ in its most basic conﬁguration illustrated in Figure 3. This
conﬁguration is suitable for straightforward production of radio-
pharmaceuticals prepared in the reaction vessel, and requiring
HPLC puriﬁcation (e.g., dihydrotetrabenazine (DTBZ), ﬂumazenil
(FMZ), meta-hydroxyephedrine (HED), PBR28, and 1-methyl-
piperidin-4-yl propionate (PMP), Figures 3 and 4, Section 2.2),
but can easily be reconﬁgured for puriﬁcation by Sep-Pak cartridge
instead (e.g., carfentanil or methionine, Section 2.3).1 However,
with some simple modiﬁcations, the TracerLab FXC-Pro
can also be used to produce radiopharmaceuticals using
other strategies such as the loop method (e.g., 3-amino-
4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (DASB),
raclopride, and Pittsburgh Compound B (PiB), Section 2.4),1
Sep-Pak reaction (e.g., choline, Section 2.5),3 or alkylation of
[11C]CO2 with Grignard reagents (e.g., acetate, Section 2.6).
4
The primarymodiﬁcationmade to the Tracerlab FXC-Pro synthesis
modules was to remove valve-30 and valve-31 from the HPLC
mobile phase set-up (Figure 3) and then use them to control ﬂow
of methyl iodide through the silver triﬂate column (Figures 4, 10,
11, and 16). The beneﬁts of such modiﬁcations are numerous. First,
control of valve-30 and valve-31 can still be controlled using the
same commands in the computer timelists, and so this allows theFigure 1. Carbon-11 labeled radiopharmaceuticals.
www.jlcr.org Copyright © 2011 John Wiley & Sonsoption for automated bypassing of the triﬂate column if synthesis
with [11C]MeI is being used. Second, it allows for enhanced system
performance when conducting loop chemistry (Section 2.4 and
Figure 11). In our early work, these valves were not in place, and
we found that after conducting loop chemistry, if the synthesismod-
ule was left over night before cleaning (not uncommon following an
afternoon or evening synthesis using 3Ci of carbon-11), then
residual liquid in the HPLC loop would leach back along the line
and poison the silver triﬂate column. Reconﬁguring valves 30 and
31 addresses this issue because they can be closed and can effec-
tively isolate and protect the silver triﬂate column from any residual
liquid in the HPLC loop. One pair of Luer Lock adapters was inserted
between valve V7 and the ﬂuid detector. These ﬁttings allow
straightforward switching from reactor chemistry to loop chem-
istry. A second pair of Luer Lock adapters was also inserted
between V14 and the round-bottomed ﬂask. This enabled crude
reaction mixtures to be injected onto a column for puriﬁcation
using semipreparative HPLC or, alternatively, to be transferred
into the round-bottomed ﬂask for puriﬁcation using solid
phase extraction (SPE) techniques without signiﬁcant module
reconﬁguration.
General synthesis considerations
Unless otherwise stated, reagents and solvents were commer-
cially available and used without further puriﬁcation: sodium
chloride, 0.9% United States Pharmacopeia (USP), and Sterile
Water for Injection, USP, were purchased from Hospira (Lake
Foest, IL, USA); ethanol was purchased from American Regent
(Shirley, NY, USA); anhydrous acetonitrile, ammonium acetate,
hydrochloric acid, acetic acid, dimethyl sulfoxide, Ascarite II,
and N,N-dimethylformamide (DMF) were purchased from Sigma
Aldrich (St. Louis, MO, USA); and HPLC grade acetonitrile was
purchased from Fisher Scientiﬁc (Pittsburgh, PA, USA). Precursors
and standards were commercially available, unless otherwise
indicated, and purchased from Aldrich (acetate, choline, carfenta-
nil (contract synthesis)), ABX Advanced Biochemicals (Radeberg,
Germany) (FMZ, DASB, HED, PBR28, PIB, Raclopride), Fluka (St., Ltd. J. Label Compd. Radiopharm 2011, 54 819–838
Figure 3. Standard HPLC Tracerlab FXC-Pro conﬁguration.
X. Shao et al.Louis, MO, USA) (methionine), Monomerchem (Research Triangle
Park, NC, USA) (DTBZ precursor (contract synthesis)), or SRI (Menlo
Park, CA, USA) (DTBZ standard (contract synthesis)). PBR28 and
PMP standards and precursors were synthesized in house17 or can
be purchased from ABX Advanced Biochemicals. Shimalite-Nickle
was purchased from Shimadzu (Columbia, MD, USA), iodine was
purchased from EMD (Rockland, MA, USA), phosphorus pentoxide
was purchased from Fluka, and molecular sieves were purchased
from Alltech (a division of Grace, Deerﬁeld, IL, USA). Other synthesis
components were obtained as follows: sterile ﬁlters were obtained
from Millipore (Billerica, MA, USA); sterile product vials were pur-
chased from Hollister-Stier (Spokane, WA, USA); C18-light Sep-Paks,Figure 4. Modiﬁed Tracerlab FXC-Pro conﬁguration for reactor/HPLC.
CopyrigJ. Label Compd. Radiopharm 2011, 54 819–838CM-light Sep-Paks, and Porapak Q were purchased from Waters
Corporation (Milford, MA, USA). C-2 and C-18 Extraction disks
were obtained from 3M (St. Paul, MN, USA). Sep-Paks and extrac-
tion disks were ﬂushed with 10mL of ethanol followed by 10mL of
sterile water prior to use. SAX Sep-Paks were purchased fromGrace
Inc. and conditioned with 10mL 70% EtOH, 5mL NaCl, 0.9% USP,
and 10mL sterile H2O prior to use.
General procedure for production of [11C]methyl iodide
Carbon-11 at the University of Michigan was produced via the
14N(p,a)11C nuclear reaction using a GEMS PETTrace cyclotronwww.jlcr.orght © 2011 John Wiley & Sons, Ltd.
821
X. Shao et al.
822equipped with a carbon-11 target. Carbon-11 was delivered from
the cyclotron target (40 mL, 30min beam provided ~3Ci of
carbon-11 as [11C]CO2) via a 1/1600 Teﬂon delivery line by
nitrogen pressure directly to a column packed with 0.3 g of
molecular sieve and 0.2 g of Shimalite–Nickle where it was
trapped at room temperature. The column was then sealed
under hydrogen gas and heated to 350C for 20 s to reduce
the [11C]CO2 to [
11C]CH4. The [
11C]CH4 was passed through a
column of phosphorous pentoxide desiccant and trapped on a
column of carbosphere cooled to 75C (with liquid nitrogen).
Gaseous [11C]CH4 was released by heating the carbosphere
column to 80C. Once released, the methane entered a circula-
tion loop, which includes a gas pump, a column of iodine at
100C, the Tracerlab standard iodine reactor tube at 720C, two
adjacent columns of Ascarite II, and a column of Porapak Q at
room temperature. The gaseous mixture was circulated for
5min, whereas [11C]MeI accumulated on the Porapak column.
[11C]MeI (~0.9 Ci) was then released from the Porapak column
and either delivered directly to the awaiting reactor (or loop),
or passed through a silver triﬂate column, by heating the
Porapak column to 190C.
General procedure for production of [11C]methyl triﬂate
[11C]CH3I was converted to [
11C]CH3OTf by passing it through a
silver triﬂate-Graphpac column pre-heated to 190C. The
contents of the silver triﬂate-Graphpac column were prepared
as follows: silver triﬂuoromethanesulfonate (5 g) was dissolved
in anhydrous acetonitrile (100mL), and the resulting solution
was transferred into a round-bottomed ﬂask containing graphite
(10 g). The mixture was stirred, and then the solvent was
evaporated to complete dryness in vacuo. The resulting [11C]
CH3OTf was delivered to the reactor, loop, or Sep-Pak as outlined
in the next paragraphs.Figure 5. Semipreparative HPLC trace for [11C]DTBZ (CPS = counts per second).
www.jlcr.org Copyright © 2011 John Wiley & SonsRadiopharmaceutical production via reactor
methylation with HPLC puriﬁcation
Production of [11C]DTBZ
Introduction
Neurodegenerative diseases are frequently associated with charac-
teristic losses of speciﬁc neurons in the human brain. For example,
progressive losses of dopaminergic neurons are typical in Parkinson’s
disease, whereas Alzheimer’s disease (AD) is associated with
decline of the cholinergic neurons. Reﬂecting this, a number of
strategies have been developed for in vivo imaging of such neu-
ronal losses using PET. One common approach is the targeting
of the vesicular monoamine transporter type 2 (VMAT2) using
radioligands such as (+)-a-[11C]dihydrotetrabenazine ([11C]DTBZ:
(2R,3R,11bR)-(1,3,4,6,7,11b-hexahydro-9-[11C]methoxy-10-methoxy)-
3-(2-methylpropyl)-2-hydroxy-2H-benzo[a]quinolizine).18,19 The
VMAT2 is not speciﬁc for a particular monoamine, but rather,
it is a common protein capable of transporting dopamine,
norepinephrine, serotonin, and histamine.20 Despite this
non-speciﬁcity, the utility of VMAT2 imaging in neurodegen-
erative disease is still possible because of the compartmenta-
lization of neuronal types in the human brain.18 For example,
dopaminergic nerve terminals predominate in the basal gang-
lia, and so enable speciﬁcity for examining losses of such
terminals in patients with Parkinson’s disease. The VMAT2 is
found in presynaptic vesicles, and is responsible for transport-
ing monoamines from the cell cytosol into the storage vesicle,
from where they can be released into the synapse.21
Synthesis procedures
To prepare DTBZ, the Tracerlab synthesis module was conﬁgured
as illustrated in Figure 4 and loaded as follows: reaction vessel:, Ltd. J. Label Compd. Radiopharm 2011, 54 819–838
X. Shao et al.(2R,3R,11bR)-9-O-desmethyldihydrotetrabenazine (DTBZ precur-
sor, 1.0mg), NaOH (7.5M, 10 mL), and DMF (100mL); Vial 1: 85/
15 20mM NaH2PO4/ethanol (1mL); Product collection vial: 0.9%
NaCl for Injection, USP (7.0mL). [11C]MeI was prepared according
to the general procedure outlined previously and then bubbled
into the reaction vessel at a ﬁxed ﬂow rate of 15mL/min for
3min. After this time, the ﬂow was stopped, and the solution
was stirred for an additional 2min. The reaction mixture was
then diluted with 85/15 20mM NaH2PO4/ethanol (1mL) and
puriﬁed using semipreparative HPLC (column: Phenomonex
Luna C8(2), 10 100mm; mobile phase: 85/15 20mM NaH2PO4/
ethanol; ﬂow rate: 3mL/min, typical trace: Figure 5). The product
fraction (3mL) was collected (retention time (RT) ~13–14min)
into the product collection vial where it was simultaneously
diluted with isotonic saline (7mL), and the resulting formulation
was passed through a 0.22mm sterilizing ﬁlter into a sterile dose
vial. The product was then submitted for quality control (QC)
testing, and typical yields of [11C]DTBZ prepared using this
method were 2.8% based upon starting [11C]CO2 (nondecay
corrected, n= 10).Production of [11C]PMP
Introduction
Acetylcholinesterase (AChE) is the enzyme responsible for the
degradation of the neurotransmitter acetylcholine, leading to
the termination of cholinergic neurotransmission. AChE deﬁcits
in postmortem AD brain samples have been observed, suggesting
that cholinergic decline is part of the complex neurodegenerative
cascade that occurs in AD.22,23 Therefore, radiopharmaceuticals
suitable for quantifying AChE in vivo have potential for tracking
the progression of the cholinergic aspect of this cascade in patientsFigure 6. Semipreparative HPLC trace for [11C]PMP.
CopyrigJ. Label Compd. Radiopharm 2011, 54 819–838with AD. The synthetic AChE substrate, 1-[11C]methylpiperidin-4-yl
propionate ([11C]PMP),24 is currently in routine clinical use as a
radiopharmaceutical for the study of AChE function in patients
with AD at both the University of Michigan and elsewhere,25–28
and results from such studies have been encouraging. For exam-
ple, statistically signiﬁcant decreases in the cortical hydrolysis rate
of [11C]PMP in AD brains, versus age-matched controls, have been
detected, and correlations identiﬁed.26,28,29
Synthesis procedures
PMP precursor was prepared as follows: 4-piperidinyl propionate
hydrochloride (0.5 0.1mg) was dissolved in aqueous saturated
sodium bicarbonate (~20 mL) and ethyl ether (2mL) was added,
and the solution was mixed vigorously on a vortex mixture for
1min. Anhydrous sodium sulfate (0.5 g) was then added to
absorb the water, and the dried ether was ﬁltered into DMF
(100 mL). The ether was evaporated under nitrogen, leaving the
precursor in DMF as freebase. To prepare [11C]PMP, the Tracerlab
synthesis module was conﬁgured as illustrated in Figure 4 and
loaded as follows: reaction vessel: [11C]PMP precursor (0.5mg
in 100mL DMF prepared as outlined previously); Vial 1: semipre-
parative HPLC mobile phase (20mM NH4OAc in 5% EtOH,
1.0mL); product collection vial: 0.9% NaCl for Injection, USP
(2.0mL). [11C]methyl triﬂate was prepared using the general
procedure outlined previously and bubbled through the precur-
sor solution at 15mL/min for 3min. The reaction mixture was
then diluted with 1mL of HPLC mobile phase and puriﬁed using
semipreparative HPLC (column: Phenomonex Luna C18,
250 10mm, mobile phase: 20mM NH4OAc in 5% EtOH, ﬂow
rate: 4mL/min, typical trace: Figure 6). The product peak was
collected (RT ~12–14min) for 2min (8mL), diluted with USP
saline (2mL) to provide a ﬁnal ethanol concentration <5%, andwww.jlcr.orght © 2011 John Wiley & Sons, Ltd.
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824passed through a 0.22 mm sterilizing ﬁlter into a sterile dose vial.
The product was then submitted for QC testing, and typical
yields of [11C]PMP prepared using this method were 3.0% based
upon starting [11C]CO2 (nondecay corrected, n=10).
Production of [11C]HED
Introduction
Radiolabeled adrenergic neurotransmitters, or closely related
analogs that actually behave as false neurotransmitters, are
routinely employed for PET imaging in oncology30 and cardiology.31
One such example, carbon-11 labeled tracer meta-hydroxyephedrine
([11C]HED or [11C]MHED), is an analog of norepinephrine that was
developed to visualize the sympathetic nervous system with PET
imaging.32 [11C]HED accumulates in nerve terminals but does not
get metabolized by catechol-O-methyl transferase or monoamine
oxidase.33 Because of these favorable characteristics, [11C]HED
can be used as a radiopharmaceutical for non-invasive assessment
of sympathetic neuronal integrity of the heart using PET
imaging.32,34 Furthermore, early clinical studies showed rapid
uptake of [11C]HED in localized tumors of the sympathetic nervous
system, and so the [11C]HED is also utilized to image such tumors
using PET.30 Our strategy for producing [11C]HED using a Tracerlab
FXC-Pro is outlined in the next paragraphs. In addition to our efforts,
related fully automated production using a Tracerlab FXC-Pro has
also been reported by Lodi and co-workers.14,33
Synthesis procedures
To prepare [11C]HED, the Tracerlab synthesis module was conﬁg-
ured as illustrated in Figure 4 and loaded as follows: reaction
vessel: metaraminol ([11C]HED precursor, 0.5 0.1mg in DMF
(50 mL)); Vial 1: semipreparative HPLC mobile phase (30mM
NH4OAc in 1% EtOH, 1.0mL); product collection vial: 0.9% NaCl
for Injection, USP (2.0mL). [11C]Methyl triﬂate was prepared
using the general procedure outlined previously and bubbledFigure 7. Semipreparative HPLC trace for [11C]HED.
www.jlcr.org Copyright © 2011 John Wiley & Sonsthrough the precursor solution at 15mL/min for 3min. The reac-
tion mixture was diluted with 1mL of HPLC mobile phase and
puriﬁed using semipreparative HPLC (column: Phenomonex
Luna C8, 150 10mm, mobile phase: 30mM NH4OAc in 1%
EtOH, ﬂow rate: 4mL/min, typical trace: Figure 7). The product
peak was collected (RT ~12min) for 2min (8.0mL), diluted with
USP saline (2.0mL) and passed through a 0.22-mm sterilizing
ﬁlter into a sterile dose vial. This product was then submitted
for QC testing, and typical yields of [11C]HED prepared using this




Flumazenil (an imidazobenzodiazepine derivative) is a benzodi-
azepine antagonist that was developed by Hoffmann-La Roche
(and marketed as Anexate).35 Flumazenil is as a competitive
inhibitor that acts on the benzodiazepine binding site of the
g–amino butyric acid A receptor and has therefore been used
as an antidote for the treatment of overdoses of both benzodi-
azepines, andnon-benzodiazepine sleep enhancers.36 Subsequently,
ﬂumazenil was developed into a radiopharmaceutical for quantifying
neuronal density, and literature methods for preparing both carbon-
1137–40 and ﬂuorine-1841–44 versions of FMZ have been reported.
For example, Aigbirhio and co-workers reported an elegant loop
method for preparing [11C]FMZ using a GEMS Microlab/Tracerlab
FXC combination.
40 [11C]FMZ is now a well-established radiophar-
maceutical used to detect epileptic foci in neocortical epilepsy,45
explore hippocampus function in patients with temporal lobe
epilepsy46 and as a marker of damage in stroke victims.43,47
Synthesis procedures
To prepare [11C]FMZ, the Tracerlab synthesis module was conﬁg-
ured as illustrated in Figure 4 and loaded as follows: reaction
vessel: desmethylﬂumazenil (1mg in DMF (100 mL) and NaOH, Ltd. J. Label Compd. Radiopharm 2011, 54 819–838
Figure 8. Semipreparative HPLC trace for [11C]FMZ.
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82(0.5M, 10mL)); Vial 1: semipreparative HPLC mobile phase (20mM
NH4OAc in 20% EtOH, 1.0mL); product collection vial: 0.9% NaCl
for Injection, USP (7.5mL). [11C]methyl iodide was generated
using the standard procedure described previously and bubbled
through the precursor solution at 15mL/min for 3min. The reac-
tion mixture was diluted with 1mL of HPLC mobile phase and
puriﬁed using semipreparative HPLC (column: Phenomonex
Luna C18, 150 10mm, mobile phase: 20mM NH4OAc in 20%
EtOH, ﬂow rate: 5mL/min, typical trace: Figure 8). The product
peak around was collected (RT ~17min) for 30 s (2.5mL) and
diluted with USP saline (7.5mL). This ﬁnal formulation was then
passed through a 0.22-mm ﬁlter into a sterile dose vial and sub-
mitted for QC testing. Typical yields of [11C]FMZ produced using




Presently, there is signiﬁcant interest in imaging the peripheral
benzodiazepine receptor (PBR), also known as the translocator
protein 18 kDa,48,49 and a number of PET biomarkers for the
PBR have been reported in recent years. The PBR is different to
the brain receptors that bind g–amino butyric acid and synthetic
benzodiazepines and is found on the outer membrane of
mitochondria in a number of cells, as well as plasma membranes
in erythrocytes. Imaging PBR using PET is of interest because PBR
has been implicated in cancer, nervous system disorders, and
neurodegenerative diseases. Moreover, an increase in PBR levels
is considered indicative of inﬂammation. Reﬂecting this, a
number of PET biomarkers that allow for imaging and evaluation
of PBR are known, of which the most common is [11C]
PK11195.50,51 However, [11C]PK11195 has limitations includingCopyrigJ. Label Compd. Radiopharm 2011, 54 819–838low brain penetration and high non-speciﬁc binding. Therefore,
new PET ligands for PBR have been developed, and we selected
N-(2-[11C]methoxybenzyl)-N-(4-phenoxy-3-pyridinyl) acetamide
([11C]PBR28),52–57 to make available to clinicians. PBR28 was
developed by Pike and colleagues and has high afﬁnity for PBR
(half maximal inhibitory concentration (IC50) = 0.658 nm) as well
as favorable pharmacokinetics and dosimetry.58
Synthesis procedures
To prepare [11C]PBR28, the Tracerlab synthesis module was
conﬁgured as illustrated in Figure 4 and loaded as follows:
reaction vessel: des-PBR28 (1mg) and 60% NaH (in dispersion
mineral oil, 1–1.3mg) in CH3CN (100 mL); Vial 1: semipreparative
HPLC mobile phase (1.0mL); Vial 4: Sterile Water for Injection,
USP (10mL); Vial 5: Ethanol (1.0mL); Vial 6: 0.9% NaCl for
Injection, USP (9.0mL); round-bottomed dilution ﬂask: HPLC
Grade Water (70mL). Ten minutes before the end of the
bombardment, des-PBR28 (1mg) and 60% NaH (in dispersion
mineral oil, 1–1.3mg) were dissolved in CH3CN (100 mL),
sonicated for 1min and transferred into the reactor. [11C]MeOTf
was prepared according to the general procedure outlined
previously and then bubbled through the reactor via He ﬂow
(12mL/min) until the activity in the reactor reached its maximum
(around 3.5min). The reactor was then sealed and heated for
3min at 80C. After cooling the reactor at 40C, the reaction
solution was diluted with HPLC eluent (1mL) and injected into
the HPLC loop for puriﬁcation using semipreparative HPLC
method (column: Phenomenex Prodigy ODS-prep 10mm
250 10mm, mobile phase: 40% MeCN: 60% water, ﬂow rate:
5mL/min, typical trace: Figure 9). The radioactive peak was
collected (RT ~17min) into the round-bottomed ﬂask containing
HPLC grade water (70mL), which was then passed through a C18
Empore Sep-Pak. Afterward, the cartridge was rinsed with Sterilewww.jlcr.orght © 2011 John Wiley & Sons, Ltd.
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826Water for Injection (10mL). The labeled compound was then
eluted off the cartridge with USP ethanol (1mL) and diluted with
Sterile 0.9% NaCl for Injection, USP (9mL). This aqueous solution
was ﬁltered through a 0.22-mm sterile ﬁlter into a sterile dose vial
and submitted for QC testing. Typical yields of [11C]PBR28 using
this method are 4.2% based upon starting [11C]CO2 (nondecay
corrected, n= 6).Figure 10. Modiﬁed Tracerlab FXC-Pro conﬁguration for loop/HPLC.
www.jlcr.org Copyright © 2011 John Wiley & SonsRadiopharmaceutical production via reactor
methylation and solid phase extraction
puriﬁcation
Radiolabeling of certain compounds with carbon-11 proceeds
cleanly (i.e., no by-products), and the radiopharmaceutical
product has sufﬁciently different polarity to the precursor that, Ltd. J. Label Compd. Radiopharm 2011, 54 819–838
X. Shao et al.puriﬁcation can be achieved using SPE or evaporation techniques.
Examples of such radiopharmaceuticals include [11C]carfentanil
and [11C]methionine, respectively. In order to prepare these radio-
pharmaceuticals, the TracerLab FXC-Pro is conﬁgured to bypass the
HPLC column (Figure 10), and the line out of the reactor (V7) is
connected directly to the round-bottomed dilution ﬂask used for
reformulation. Reformulation then proceeds as normal (Figure 3).
Production of [11C]carfentanil
Introduction
During the mid-1960s, binding studies using brain homogenates
made it apparent that opioid agents probably act through
interaction with speciﬁc receptors, and the ﬁrst to be identiﬁed
were the mu-opioid receptors.59,60 The mu-opioid receptors are
an important class of receptors, with roles in mediating pain
and feelings of well-being.61 Carfentanil, one of the most potent
opioids known, has been shown to bind very speciﬁcally with
mu-opioid receptors as a full agonist. Reﬂecting this discovery,
[11C]carfentanil has found widespread use as a radiopharmaceu-
tical for measuring and mapping the mu-opioid receptors
in vivo.62,63 A number of syntheses have been reported,1,64–68
and [11C]carfentanil has been used to explore many normal
and altered neurophysiological and psychic phenomena.
Synthesis procedures
To prepare [11C]carfentanil, the Tracerlab synthesis module was
conﬁgured as illustrated in Figure 10 and loaded as follows:
reaction vessel: desmethyl carfentanil - tetrabutyl ammonium
(TBA) salt (0.4mg in dimethyl sulfoxide (100 mL)); Vial 1: 1%
ammonium hydroxide (1mL); Vial 3: 10% n-propanol (3mL); Vial
4: Milli-Q Water (7mL); Vial 5: Ethanol (0.5mL); Vial 6: Sterile
Water for Injection (9.5mL); round-bottomed dilution ﬂask: 1%
ammonium hydroxide (5mL). [11C]methyl triﬂate was preparedFigure 11. Semipreparative HPLC trace for [11C]DASB.
CopyrigJ. Label Compd. Radiopharm 2011, 54 819–838using the general procedure outlined previously and bubbled
through the precursor solution at 15mL/min at room temperature
for 3min. After production, 1% ammonium hydroxide (1mL) was
added to the reaction vessel. The crude reaction mixture was then
conveyed via helium gas to the dilution ﬂask containing 5mL of
1% ammonium hydroxide. This mixture was passed through a
3M Empore C2 extraction disk where the [11C]carfentanil was
trapped. Three milliliters of 10% n-propanol followed by 7mL
Milli-Q water were then passed through to remove impurities
from the disk. The disk was then dried by passing helium gas
through for 1.0min, and the [11C]carfentanil was eluted off with
ethanol (0.5mL) and diluted with Sterile Water for Injection
(9.5mL). The formulated product was then passed through a
0.22-mm ﬁlter into a sterile dose vial, and the product was sub-
mitted for QC testing. Typical yields of [11C]carfentanil prepar-
ing using this method were 6.3% based upon starting [11C]
CO2 (n= 10).Production of [11C]methionine
Introduction
Methionine is a naturally occurring amino acid that is a key
component of protein biosynthesis.69,70 As tumor cells are grow-
ing more rapidly than corresponding non-cancerous cells, the
formation of new proteins is more rapid in cancerous cells. This
increased rate of growth can be detected using PET imaging
with [11C]methionine ([11C]MET), and thus, [11C]MET can be
considered a biomarker of cell proliferation like, for example,
[18F]FDG and [18F]FLT. Although [11C]MET has been used to
image a variety of tumors,71,72 the majority of its clinical use to
date has been for imaging brain tumors such as gliomas.73,74 A
number of strategies for preparing [11C]methionine having been
reported,75–79 including recent developments that eliminate the
need for HPLC puriﬁcation.80–82www.jlcr.orght © 2011 John Wiley & Sons, Ltd.
827
X. Shao et al.
828Synthesis procedures
To prepare [11C]methionine, the Tracerlab synthesis module was
conﬁgured as illustrated in Figure 10 and loaded as follows:
reaction vessel: L-homocysteine thiolactone (2.0mg) dissolved
sodium hydroxide (0.1 M, 0.5mL) and acetone (0.5mL); Vial 1:
0.9% NaCl for Injection, USP (1.0mL); round-bottomed dilution
ﬂask: 45mM Sodium Phosphates for Injection, USP (0.5mL) +
0.9% NaCl for Injection, USP (8.5mL). [11C]CH3I was made
according to the general procedure outlined previously and then
bubbled through the solution of L-homocysteine thiolactone at
15mL/min for 3min. After reaction, the acetone and residual
[11C]CH3I were evaporated at 55C under a helium gas stream
for 5min. The product was then redissolved in 0.9% NaCl for
Injection, USP (1.0mL) and passed into the round-bottomed
ﬂask charged with 45mM sodium phosphates, USP (0.5mL)
and additional 0.9% NaCl for Injection, USP (8.5mL). This ﬁnal
formulation was then passed through a 0.22-mm ﬁlter into a
sterile dose vial and submitted for QC testing. Yields of methio-
nine using this method are typically 4.0% based upon starting
[11C]CO2 (nondecay corrected, n= 4).Radiopharmaceutical production via loop
methylation and HPLC puriﬁcation
Loop chemistry, an early form of microﬂuidics, has proven a
particularly efﬁcient strategy for radiolabeling with carbon-11.
A solution of the precursors is deposited as a thin ﬁlm on the
inside of an HPLC loop. The reaction then occurs by blowing
[11C]MeI (or [11C]MeOTf) through the HPLC loop, to generate
the product. Following reaction, the valve is switched to ‘inject’,
and the contents of the loop are washed by using HPLC mobile
phase and injected onto the HPLC column for immediate
puriﬁcation. Examples of such radiopharmaceuticals particularlyFigure 12. Semipreparative HPLC trace for [11C]PiB.
www.jlcr.org Copyright © 2011 John Wiley & Sonsamenable to loop synthesis include [11C]DASB, [11C]PiB, and
[11C]raclopride. In order to prepare these radiopharmaceuticals
using a TracerLab FXC-Pro, the synthesis module had to be
reconﬁgured to deliver methyl triﬂate directly to the HPLC loop,
as shown in Figure 11. Following HPLC puriﬁcation, fraction
collection and/or reformulation proceeds as normal (Figure 3).Production of [11C]DASB
Introduction
Serotonin is one of the monoamine neurotransmitters. Extracel-
lular levels of serotonin in the synaptic cleft are controlled by
the serotonin transporter (SERT), which can decrease serotonins
level through reuptake.83 Serotonin is widely known to inﬂuence
feelings of well-being, whereas, conversely, dysfunction of the
SERT (and corresponding disruption of serotonin levels) has
been implicated in a range of psychiatric disorders including
schizophrenia,84 depression,85,86 and anxiety.86 Reﬂecting this,
SERT is the target for the selective serotonin reuptake inhibitors,
a widely used class of antidepressant drugs,87 and SERT imaging
has proven to be an important tool for managing these disorders
with, for example, PET imaging. [11C]-3-amino-4-(2-dimethylami-
nomethylphenylsulfanyl)-benzonitrile ([11C] DASB) is a compound
that binds to the serotonin transporter and is the radioligand of
choice for imaging the SERT transporter,84,88–90 because of a
number of characteristics that make it an attractive ligand for
clinical imaging. For example, it has high afﬁnity for the SERT
(1.1nM), excellent selectivity over the corresponding norepi-
nephrine and dopamine transporters (NET/SERT=1230nM and
DAT/SERT=1300nM, respectively); high speciﬁc binding and,
ﬁnally, high (but reversible) brain uptake.91 Syntheses of [11C]
DASB have been reported, for example, by Wadsak and
colleagues.88,91, Ltd. J. Label Compd. Radiopharm 2011, 54 819–838
X. Shao et al.Synthesis procedures
To prepare [11C]DASB, the Tracerlab synthesis module was
conﬁgured as illustrated in Figure 11 and loaded as follows:
2mL steel HPLC loop: O-desmethyl DASB (1.0mg) in 2-butanone
(100 mL); Vial 4: Sterile Water for Injection, USP (7mL); Vial 5: Etha-
nol (0.5mL); Vial 6: 0.9% NaCl for Injection, USP (9.5mL); round-
bottomed dilution ﬂask: Milli-Q Water (50mL). The precursor
solution was loaded onto the HPLC loop (2mL, steel) and condi-
tioned with nitrogen gas for 20 s at 10mL/min. [11C]MeOTf was
prepared according to the general procedure outlined
previously and passed through the HPLC loop at 40mL/min for
3min. Following reaction, the mixture was puriﬁed using
semipreparative HPLC (column: Phenomonex Luna C18,
250 10mm, mobile phase: 100mM NH4OAc in 30% MeCN,
pH= 5.5, ﬂow rate: 4mL/min, typical trace: Figure 12). The
product peak (RT ~10min) was collected into 50mL of water.
The solution was then passed through a C18 Sep-Pak to remove
organic solvent and washed with 7mL sterile water. The product
was then eluted with 0.5mL of USP ethanol followed by 9.5mL
of USP saline. This ﬁnal formulation was then passed through a
0.22-mm ﬁlter into a sterile dose vial and released for QC testing.
Typical yields of [11C]DASB prepared using this method are 4.0%
based upon starting [11C]CO2 (nondecay corrected, n=10).
Production of [11C]Pittsburgh compound B
Introduction
Alzheimer’s disease affects 5.3 million Americans, and this
number is expected to rise as the baby boom generation comes
of age. The cause of AD is presently not entirely understood but
what is clear is that it results from a complex neurodegenerative
cascade that includes misfolding and aggregation of proteinsFigure 13. Semipreparative HPLC trace for [11C]raclopride.
CopyrigJ. Label Compd. Radiopharm 2011, 54 819–838such as amyloid and tau, with concomitant decline of neuro-
transmitter systems.92–94 Although AD can be predicted by
clinical diagnosis,95 differentiating it from other clinically and
neuropathologically overlapping dementia diseases can only be
achieved deﬁnitively by high-risk diagnostic procedures (e.g.,
brain biopsy) or, more commonly, post mortem.96 This makes it
difﬁcult to (a) differentiate AD from other dementias and treat
each appropriately before patient death; (b) manage AD early,
before cognitive decline; (c) select patients for assisting in AD
drug development; and (d) track the impact of new AD thera-
peutics in clinical trials. Therefore, new non-invasive diagnostic
methods for managing AD are in high demand, and PET imaging
has enormous potential to impact health care in this regard.
Important radioactive drugs that allow diagnosis of AD by visua-
lization of amyloid plaques using PET imaging have been devel-
oped (e.g., [18F]Amyvid ([18F]Florbetapir),97 [18F]Florbetaben,98
[18F]Flutemetamol,99 [11C]Pittsburgh Compound B ([11C]PIB)100)
and are in advanced clinical trials. For example, [11C]PIB is a radi-
olabeled analog of a dye used to stain amyloid by pathologists
(thioﬂavin-T). [11C]PIB was developed by Mathis and Klunk,101
although a number of syntheses have since been reported,15,102,103
and can be used to non-invasively image (and quantify) beta-
amyloids plaques in vivo using PET imaging.100
Synthesis procedures
To prepare [11C]PiB, the Tracerlab synthesis module was conﬁg-
ured as illustrated in Figure 11 and loaded as follows: 2mL steel
HPLC loop: 2-(4′-aminophenyl)-6-hydroxybenzothiazole (1.0mg)
in 3-pentanone (100 mL); Vial 4: Sterile Water for Injection, USP
(7mL); Vial 5: Ethanol (0.5mL); Vial 6: 0.9% NaCl for Injection,
USP (9.5mL); round-bottomed dilution ﬂask: Milli-Q Water
(50mL). The precursor solution was loaded onto the HPLC loopwww.jlcr.orght © 2011 John Wiley & Sons, Ltd.
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830(2mL, steel) and conditioned with nitrogen gas for 20 s at 10mL/
min. The [11C]methyl triﬂate was passed through the HPLC loop
at 15mL/min for 5min. The reaction mixture was then puriﬁed
using semipreparative HPLC (column: Phenomonex Luna C18,
150 10mm, mobile phase: 50mM NH4OAc in 40% MeCN, ﬂow
rate: 5mL/min, typical HPLC trace: Figure 13). The product peak
(RT ~8min) was collected into 50mL of water. The solution was
then passed through a C-18 extraction disk to remove organic
solvent. The disk was washed with 7mL sterile water. The pro-
duct was eluted with 0.5mL of USP ethanol followed by 9.5mL
of USP saline. This ﬁnal formulation was then passed through a
0.22-mm ﬁlter into a sterile dose vial and released for QC analysis.
Typical yields of [11C]PiB prepared using this method are 1.6%
based upon starting [11C]CO2 (nondecay corrected, n=10).
Production of [11C]raclopride
Introduction
[11C]Raclopride, a substituted benzamide, is a radiopharmaceuti-
cal used for visualization and quantiﬁcation of D2-like dopamine
receptors using PET imaging.104,105 [11C]Raclopride has been
used to study neuropsychiatric disorders related to dopamine D2
receptors for years.106–108 Several different synthetic approaches
have been reported, as well as different automated modules for
production of [11C]raclopride. Both [11C]methyl iodide and [11C]
methyl triﬂate have been used for [11C]methylation ofO-desmethyl
raclopride in the presence of base.109–112 Recently, the loop
methylation strategy has also become more popular for prepar-
ing [11C]raclopride because of its high efﬁciency.11,113–116 With
the increasing demand for this radiopharmaceutical, we have
recently developed a fully automated and reliable loop method
to produce [11C]raclopride for routine clinical application in high
radiochemical yield and purity.1Figure 14. Semipreparative HPLC trace for [11C]PBR-28.
www.jlcr.org Copyright © 2011 John Wiley & SonsSynthesis procedures
To prepare [11C]raclopride, the Tracerlab synthesis module was
conﬁgured as illustrated in Figure 11 and loaded as follows:
2mL steel HPLC loop: O-desmethyl raclopride tetrabutyl ammo-
nium salt (1.0mg) in 2-butanone (100mL); product collection vial:
0.9% NaCl for Injection, USP (5.5mL). The precursor solution was
slowly injected into HPLC loop. [11C]CH3OTf was prepared
according to the general procedure described previously and
passed through the loop at a ﬂow rate 40mL/min. After 3min,
the reaction mixture was injected onto a HPLC column and
puriﬁed using semipreparative HPLC (column: Phenomonex
Luna NH2, 250 10 mm, mobile phase: 20mM NH4OAc in 10%
ethanol, ﬂow rate: 3mL/min, typical HPLC trace: Figure 14). The
product peak (RT ~10min) was collected for 90 s (4.5mL) directly
into the product vial containing USP saline (5.5mL). The ﬁnal
dose was ﬁltered through a 0.22-mm sterile ﬁlter into a dose vial
and submitted for QC testing. Typical yields of [11C]raclopride
prepared using this method are 2.2% based upon starting [11C]
CO2 (nondecay corrected, n= 10).
Concomitant production and puriﬁcation of
radiopharmaceuticals using solid phase
extraction cartridges
In addition to being used for puriﬁcation of radiopharmaceu-
ticals, in certain cases, SPE Sep-Pak cartridges can also be
used (alone or in series) as the reaction vessel. The reaction
then occurs by blowing [11C]MeI (or [11C]MeOTf) over an SPE
cartridge, previously charged with precursor, to generate the
product. Following reaction, puriﬁcation can then be achieved
by using standard removal of impurities and then elution of
the product as previously described. We routinely employ this
strategy for preparation of [11C]choline. In order to automate, Ltd. J. Label Compd. Radiopharm 2011, 54 819–838
Figure 15. Modiﬁed Tracerlab FXC-Pro conﬁguration for solid phase extraction reaction/puriﬁcation.
X. Shao et al.preparation of [11C]choline using a TracerLab FXC-Pro, the synth-
esis module had to be reconﬁgured to deliver methyl iodide
directly to the SPE cartridge, as shown in Figure 15. Following
reaction, puriﬁcation and reformulation proceeds as normal,
utilizing vials 4, 5, and 6.Production of [11C]choline
Introduction
Choline is a salt that is found in all cells where it is used in the
biosynthesis of phospholipids. Such phospholipids are thenFigure 16. Modiﬁed Tracerlab FXC-Pro conﬁguration for addition of Grignard to [
11C]
CopyrigJ. Label Compd. Radiopharm 2011, 54 819–838incorporated into cell membranes, and therefore, radiolabeled
analogs of choline can be used to monitor the rate of production
of cell membranes in vivo, and thus the rate of cell proliferation.
[11C]choline, and more recently [18F]ﬂuoromethylcholine, have
been employed as biomarkers for imaging human brain, lung,
and prostrate cancers.117 To support the increasing demand for
[11C]choline, a number of synthetic approaches have been
reported,15,118–121 the most common of which uses a C18 Sep-
Pak as a solid support for methylation and, subsequently, a CM
Sep-Pak for puriﬁcation. We have produced [11C]choline
manually using this method, but when adapting this procedure
for automation using the TracerLab FXC-Pro, the back pressureCO2.
www.jlcr.orght © 2011 John Wiley & Sons, Ltd.
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832of two adjacent Sep-Pak cartridges signiﬁcantly slowed down
liquid transfers during the synthesis, resulting in lower yields
and speciﬁc activity of the ﬁnal dose. To address this problem,
we recently reported an optimized method for producing [11C]
choline using only one CM Sep-Pak for both reaction and
puriﬁcation.3,122 The low back pressure of this system enabled
efﬁcient and reliable production of [11C]choline using a
TracerLab FXC-Pro.
Synthesis procedures
To prepare [11C]choline, the TracerLab FXC-Pro was conﬁgured as
shown in Figure 15 and loaded as follows: CM Sep-Pak: 40 mL of
N,N-dimethylaminoethanol (DMAE) dissolved in 20 mL of ethanol;
Vial 4: ethanol (5mL); Vial 5: 0.9% NaCl for Injection, USP (0.5mL);
Vial 6: Sterile Water for Injection, USP (9.5mL); round-bottomed
dilution ﬂask: Sterile Water for Injection, USP (20mL). The
three-way valve V30 was borrowed from HPLC unit and inserted
between the round-bottomed ﬂask and V11. This valve (V30) is
conﬁgured normally open to V17, which allows [11C]methyl
iodide going to Sep-Pak through V11 for reaction. Activating this
valve diverts water from the round-bottomed dilution ﬂask to
the Sep-Pak for washing. [11C]Choline was synthesized by [11C]
methylation of DMAE with [11C]methyl iodide. Forty microliters
of DMAE was dissolved into 20mL of ethanol and loaded onto
a CM Sep-Pak. The Sep-Pak was then installed on the synthesis
module between V11 and V12. [11C]Methyl iodide was produced
according to the general procedure outlined previously and
subsequently passed through the CM Sep-Pak at 20mL/min ﬂow
rate for 3min. After this time, the Sep-Pak was washed with 5mL
of ethanol (from Vial 4) and 20mL of water (from round-
bottomed ﬂask). The product was eluted with 0.5mL of USP
saline (from Vial 5), followed by 9.5mL of USP water (from Vial
6) into the product vial. The ﬁnal dose was then transferred into
a sterile dose vial through a 0.22-mm sterile ﬁlter and submitted
for QC testing. Typical yields of [11C]choline produced using this
method were 7.3% based upon starting [11C]CO2 (nondecay
corrected, n= 10).
Radiopharmaceutical production via
alkylation of [11C]CO2 with Grignard reagents
Finally, certain radiopharmaceuticals can be prepared directly
from [11C]CO2. In such cases, the synthesis module has to be
reconﬁgured to bypass the methyl iodide and methyl triﬂate
production loop, so that [11C]CO2 can be bubbled directly
through the reaction vessel. For example, we recently reported
method for preparing [11C]acetate, in which a Tracerlab FXC-Pro
was reconﬁgured (as shown in Figure 16) to allow full automa-
tion of the synthesis.4
Production of [11C]acetate
Introduction
Although the viability of [11C]acetate as a PET radiopharmaceuti-
cal was ﬁrst described almost 30 years ago,123 its application in
myocardial imaging has continued to be of interest since its
introduction.124,125 However, myocardial imaging was quickly
discovered to be only a single application of [11C]acetate. By
entering the Krebs cycle in the form of the acetyl group in acetyl
coenzyme A (acetyl CoA),126 cells undergoing more or less
cellular respiration relative to the surrounding cells are easily
identiﬁable. Thus, recent studies have reported use of [11C]www.jlcr.org Copyright © 2011 John Wiley & Sonsacetate for imaging meningiomas,127 renal carcinomas,128 and
liver and prostate tumors.129–132 Strategies for the synthesis of
[11C]acetate have been reported by our group,4 Boschi,133,134
and others.15,135–140
Synthesis procedures
In order to prepare [11C]acetate, the Tracerlab FXC-Pro was conﬁg-
ured as shown in Figure 16 and as previously described.4 Vials
were loaded as follows: reaction vessel: CH3MgCl in THF (0.5 M,
200 mL); Vial 2: CH3CO2H (1mM, 1mL); Vial 3: CH3CO2H (1mM,
2mL); Vial 4: Sterile Water for Injection (10mL); Vial 6: 0.9% NaCl
for Injection, USP (10mL); round-bottomed dilution ﬂask:
CH3CO2H (1mM, 5mL). The methyl iodide Porapak column was
replaced with a second column of molecular sieves, and we
installed an electronic valve (Valve E in Figure 16), which directed
[11C]CO2 from the exhaust line of V27 to this second column of
molecular sieves. The reaction vessel was pre-charged with
200 mL 0.5 M CH3MgCl/THF after it had been evacuated of all
atmospheric gases via nitrogen ﬂow, and the second molecular
sieve column was pre-charged with 1mL of [12C]CO2 prior to
introduction of activity (addition of [12C]CO2 eliminated over
alkylation of [11C]CO2 by the Grignard). The line out from V7
was connected to the round-bottomed dilution ﬂask. This bypass
permitted the transfer of the product from the reaction vessel
directly to the dilution ﬂask after quenching. Luer Lock adapters
were inserted between the dilution ﬂask and V11 to accommo-
date PS-H+ and PS-Ag+ Sep-Paks. Similarly, the cradle (normally
used for the C18 Sep-Pak) was used for the SAX Sep-Pak.
[11C]CO2 was delivered to the Tracerlab FXC-Pro module for
2min and retained on the ﬁrst molecular sieve column (normally
the Shimalite oven). These sieves were then heated to 350C, at
which point the ﬂow rate was decreased to 15mL/min, to
transfer the [11C]CO2 to the second column of molecular sieves
(pre-charged with [12C]CO2). This second column of sieves was
heated to 250C, V31 and V30 were opened, and the resulting
gaseous mixture of [11C]CO2/[
12C]CO2 was bubbled through the
solution of CH3MgCl in the reactor for 4min, and stirred for an
additional 30 s after bubbling had concluded. The reaction was
then quenched with 1mM CH3CO2H (1mL from Vial 2). The crude
reaction mixture was then transferred to the dilution ﬂask where
it was further diluted into 5mL of 1mM CH3CO2H. A ﬁnal 2mL of
1mM CH3CO2H was added (from Vial 3) via the reactor. The
resulting solution was then passed through PS-H+ and PS-Ag+
Sep-Paks (to remove excess acid, magnesium, or halide ions,
respectively) before passing through a Maxiclean SAX anion
exchange column where the [11C]acetate was trapped on the
cartridge. The SAX column was rinsed with 10mL sterile H2O
(from Vial 4), and then [11C]acetate was eluted off the column
with 10mL NaCl, 0.9% USP (from Vial 6), and collected into the
product collection ﬂask. Finally, the product was passed through
a sterile 0.22-mm sterile ﬁlter into a sterile dose vial and
submitted for QC testing. Typical yields of [11C]acetate prepared
using this method were 8.1% based upon starting [11C]CO2
(nondecay corrected, n=5).
Synthesis module cleaning
The radiopharmaceuticals described in Sections 2.2–2.6 can be
prepared on a single Tracerlab FXC-Pro. Changing between
module conﬁgurations is that modiﬁcations described in Section
2.1 are made to the Tracerlab. In order to clean and dry the
synthesis module between syntheses, however, the Tracerlab is, Ltd. J. Label Compd. Radiopharm 2011, 54 819–838
Table 1. Representative quality control data
QC test Release criteria Acetate Carfentanil Choline DASB DTBZ FMZ
n N/A 5 10a 10a 10a 10a 7
Starting activity (mCi) N/A 3000 3000 3000 3000 3000 3000
Mean yield (mCi) @
end-of-synthesis
(EOS)
N/A 244 188.5 219.0 119.6 82.6 89.3
% Yield (nondecay
corrected)
N/A 8.1% 6.3% 7.3% 4.0% 2.8 3.0%
Speciﬁc activity (Ci/m
mol)
N/A ND 39 746 ND 5239 6436 11 214
Appearance Clear, colorless, free of
particulates
Pass Pass Pass Pass Pass Pass
pH 4.5–8.0 6.0 5.0 5.0 5.8 5.0 5.8
Radiochemical purity >95% by HPLC 99.3% 97.9% 99.9% 98.0% 99.7 100%
Radiochemical
identity
RRT= 0.9–1.1 1.03 1.01 1.09 1.03 1.02 1.01
Radionuclidic identity T1/2 = 18.4–22.4min 20.2 20.0 20.2 ND 20.2 ND
Residual solvent
analysis
Dimethyl sulfoxide (<5000mg/mL) N/A 3 N/A ND N/A ND
n-Propanol (<5000mg/mL) N/A 4 N/A N/A
DMF (<880mg/mL) N/A N/A N/A 81.5




THF (<5000 mg/mL) <LOD N/A N/A N/A
DMAE (<20mg/mL) N/A N/A 5.36 N/A
Filter integrity test >40 psi >50 psi >45 psi >50 psi ND >50 psi ND
Bacterial endotoxins <17.5 EU/mL <2.00 <2.00 <2.00 <2.00 <2.00 <2.00
Sterility Sterile Sterile Sterile Sterile Sterile Sterile Sterile
aWe have made hundreds of doses of these radiopharmaceuticals using the methods outlined herein. The n values included are for
a limited number of representative batches.
DASB, [(di(methyl)amino)methyl]phenyl]sulfanylbenzonitrile; DTBZ, dihydrotetrabenazine; FMZ ﬂumazenil, N/A, not applicable; ND,
not determined; EU, endotoxin units; QC, quality control; DMF, N,N-dimethylformamide; DMAE, N,N-dimethylaminoethanol; RRT,
relative retention time.
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83returned to its basic conﬁguration (Figure 4) after completion of
a given synthesis, and then daily and weekly clean cycles are per-
formed as outlined in the next paragraphs. Note that the round-
bottomed dilution ﬂask and product collection vial are removed,
washed, and oven-dried separately between syntheses and after
completion of the cleaning cycles. The reaction vessel should be
checked afterward to ensure cleanliness and can also be further
cleaned and oven-dried manually if required.
Daily clean cycle
The module is reset to its normal conﬁguration illustrated in
Figure 4. Between daily runs, we wash and dry the vials, reaction
vessel, and HPLC loop. The vials are loaded as follows: Vial 1:
water (1mL); Vial 2: acetone (1mL); Vial 3: acetone (3mL); Vial
4: ethanol (10mL); Vial 5: ethanol (10mL); Vial 6: 70% ethanol
(10mL). The water from Vial 1 is initially passed through the
reactor and the HPLC loop to waste, followed by the acetone.
Helium is then blown through for 5min to dry the HPLC loop.
The reaction vessel is then heated to 80C and placed under
vacuum for 5min to dry it. The reformulation components are
also then cleaned with ethanol and dried by using helium ﬂow.
The daily clean cycle takes approximately 20min.CopyrigJ. Label Compd. Radiopharm 2011, 54 819–838Weekly clean cycles
The module is reset to its normal conﬁguration illustrated in
Figure 4. Once per week, we wash and dry the vials, reaction
vessel, and HPLC loop. The ﬁrst ‘clean’ cycle washes everything
with water (Vials 1–6 are ﬁlled with water). This is followed by
a ‘clean/disinfect’ cycle (Vials 1–6 are ﬁlled with 70% ethanol),
and ﬁnally, a ‘dry’ cycle (Vials 1–3 are ﬁlled with acetone and vials
4–6 are ﬁlled with ethanol). During the ‘clean’ and ‘clean/disinfect’
programs, water and 70% ethanol are washed through the reactor
and the HPLC loop to waste, respectively. The dry cycle washes
acetone through the reaction vessel and HPLC loop to waste,
before heating the reaction vessel to 80C and placing it under
vacuum for 5min. During the ‘dry’ cycle, the reformulation
components are cleaned with ethanol and dried by using
helium ﬂow.Quality control procedures
Quality control of radiopharmaceuticals prepared for clinical use
at the University of Michigan PET Center is carried out using
guidelines outlined in Chapter 823 of USP and as detailed in
the next paragraphs.141 After successfully meeting releasewww.jlcr.orght © 2011 John Wiley & Sons, Ltd.
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Table 2. Representative quality control data (continuation)
QC test Release criteria HED Methionine PBR28 PMP PiB Raclopride
n N/A 10a 4 6 10a 12a 10a
Starting activity (mCi) N/A 3000 1500 3000 3000 3000 3000
Mean Yield (mCi) @ EOS N/A 87.7 120.5 119 90.2 46.9 64.4
% Yield (nondecay
corrected)
N/A 2.9% 8.0% 4.0% 3.0% 1.6% 2.2%
Speciﬁc activity (Ci/mmol) N/A 1884 <LOD 12 000 <LOD 7177 8325
Appearance Clear, colorless, free of
particulates
Pass Pass Pass Pass Pass Pass
pH 4.5–8.0 6.0 6.3 5.0 6.3 5.0 5.6
Radiochemical purity >95% by HPLC 100% 96.7% 100% 98.0% 98.8% 98.2%
Radiochemical identity RRT = 0.9–1.1 1.03 <LOD 1.01 <LOD 1.01 1.01
Radionuclidic identity T1/2 = 18.4–22.4min 20.2 20.3 20.2 20.2 20.2 20.0
Residual solvent analysis MeCN (<410mg/mL) ND N/A 25 ND 3.6 N/A
Butanone (<5000mg/mL) N/A N/A N/A <LOD
Acetone (<5000mg/mL) 1201 145 139.4 9.3
Ether (<5000 mg/mL) N/A N/A N/A N/A
3-Pentanone (400 mg/mL) N/A N/A 3.9 N/A
Filter integrity test >40 psi ND >50 psi >40 psi ND >50 psi >50 psi
Bacterial endotoxins <17.5 EU/mL <2.00 <2.00 <2.00 <2.00 <2.00 <2.00
Sterility Sterile Sterile Sterile Sterile Sterile Sterile Sterile
aWe have made hundreds of doses of these radiopharmaceuticals using the methods outlined herein. The n values included are for
a limited number of representative batches.
HED, meta-hydroxyephedrine; PMP, 1-methylpiperidin-4-yl propionate; PiB, Pittsburgh Compound B; N/A, not applicable; ND, not
determined; EU, endotoxin units; QC, quality control; RRT, relative retention time.
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834criteria (Tables 1 and 2), doses are released to physicians for
clinical use.Visual inspection
Doses are visually examined and must be clear, colorless, and
free of particulate matter.Dose pH
The pH of the doses is analyzed by applying a small amount of
the dose to colorpHastW pH 2.0–9.0 non-bleeding pH indicator
strips and determined by visual comparison to the scale
provided.Chemical purity and radiochemical purity/identity
Chemical and radiochemical purity/identity are analyzed using a
Shimadzu VP-Series HPLC equipped with a Bioscan FC3300
radioactivity detector and either a conductivity detector ([11C]
choline) or a UV detector ([11C]acetate, [11C]carfentanil,
[11C]DASB, [11C]DTBZ, [11C]FMZ, [11C]HED, [11C]methionine, [11C]
PBR28, [11C]PiB, [11C]PMP, and [11C]raclopride) using conditions
described in the next paragraphs. Although radiochemical purity
for doses typically must be >95%, there are currently no chemi-
cal purity requirements for release of radiopharmaceuticals in
clinical research. Radiochemical identity is conﬁrmed and quanti-
ﬁed by calculating the relative retention time ( = [retention time
of radiochemical peak]/[retention time of unlabeled reference
standard peak]).www.jlcr.org Copyright © 2011 John Wiley & Sons[11C]Acetate
Column: Phenomonex Luna SCX, 150 4.6mm; 0.5 N (0.25M)
aqueous sulfuric acid; ﬂow rate: 1.0mL/min; UV: 220 nm; RT = 7.0
min. [12C]Sodium acetate was purchased from Sigma Aldrich
and used as the non-radioactive reference standard.[11C]Carfentanil
Column: Phenomenex Luna C8(2) 5m, 100 2.0mm; mobile
phase: 35% MeOH: 65% 20mM NH4OAc; pH 4.5; ﬂow rate:
0.8mL/min; oven: 40C; UV: 218nm; RT=4.5min. Non-radioactive
[12C]carfentanil was used as the reference standard.[11C]Choline
Column: Waters IC-Pak Cation M/D Column, 150 3.9mm;
mobile phase: 5mM aqueous hydrochloric acid, ﬂow rate:
1.0mL/min; conductivity detector: negative polarity; RT = 7.0–
7.5min. [12C]Choline non-radioactive reference standard was
purchased from Sigma Aldrich.[11C]DASB
Column: Phenomonex Luna C18 5 m, 100 2.0mm; mobile
phase: 35% MeOH: 65% 20mM NH4OAc; pH: 4.5; ﬂow rate:
0.3mL/min; oven: 30C; UV: 254 nm; RT = 4.5min. [12C]DASB
non-radioactive ﬂuoride-19 reference standard was purchased
from ABX Advanced Biochemicals., Ltd. J. Label Compd. Radiopharm 2011, 54 819–838
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83[11C]DTBZ
Column: Phenomonex Luna C8(2) 5m, 100 2.0mm; mobile
phase: 25% MeOH: 75% 20mM aqueous NH4OAc; pH 4.5; ﬂow
rate: 0.7mL/min, oven: 40C; UV= 240 nm; RT = 1.8min. [12C]
DTBZ reference standard was purchased from SRI (contract
synthesis).
[11C]FMZ
Column: Phenomonex Luna C8(2) 5m, 100 2.0mm; mobile
phase: 25% MeOH: 75% 20mM NH4OAc; pH: 4.5; ﬂow rate:
0.8mL/min; oven: 40C; UV: 240 nm; RT = 6.0min. [12C]FMZ non-
radioactive reference standard was purchased from ABX
Advanced Biochemicals.
[11C]HED
Column: Phenomonex Luna C18(2) 5m, 150 2.0mm; mobile
phase: 5% MeOH: 95% 20mM NH4OAc; pH: 4.5; ﬂow rate:
0.25mL/min; oven: 30C; UV: 280 nm; RT = 8.1min. [12C]HED
non-radioactive reference standard was purchased from ABX
Advanced Biochemicals.
[11C]Methionine
Column: Phenomonex Luna C18(2) 5m, 150 4.6mm; mobile
phase: 8mM Cu(OAc)2: 17mM L-proline: 30mM NaOAc; ﬂow rate:
1.5mL/min; oven: 40C; UV: 304nm; RT=10.7min. [12C]Methionine
non-radioactive reference standard was purchased from
Fluka.
[11C]PBR28
Column: Phenomonex Luna C18(2) 5m, 150 4.6mm; mobile
phase: 45% MeCN: 10mM Ammonium Formate; ﬂow rate:
3.0mL/min; oven: 40C; UV: 220 nm; RT = 2.4–2.5min. [12C]
PBR28 non-radioactive reference standard was prepared in
house17 (although it is also now commercially available from
ABX Advanced Biochemicals).
[11C]PiB
Column: Phenomenex Luna C8(2) 5 m, 100 2.0mm; mobile
phase: 45% MeOH: 55% 20mM NH4OAc; pH 4.5; ﬂow rate:
0.6mL/min; oven: 40C; UV: 350 nm; RT = 4.0min. [12C]PiB non-
radioactive reference standard was purchased from ABX
Advanced Biochemicals.
[11C]PMP
Column: Phenomonex Luna C18(2) 5m, 150 2.0mm; mobile
phase: 5% MeOH: 95% 20mM NH4OAc; pH 4.5; ﬂow rate:
0.35mL/min; UV: 220 nm; RT = 4.5min. [12C]PMP non-radioactive
reference standard was purchased from ABX Advanced
Biochemicals.
[11C]Raclopride
Column: Phenomenex Luna C8(2) 5 m, 100 2.0mm; mobile
phase: 35% MeOH: 65% 20mM NH4OAc; pH 4.5; ﬂow rate:
0.8mL/min; oven: 40C; UV: 218 nm; RT = 3.5min. [12C]Raclopride
non-radioactive reference standard was purchased from ABX
Advanced Biochemicals.CopyrigJ. Label Compd. Radiopharm 2011, 54 819–838Residual solvent analysis
Levels of residual solvents in doses were analyzed using a
Shimadzu GC-2010 with an AOC-20 autoinjector, split/splitless
inlet, a ﬂame ionization detector, and a Restek column (Stabilwax
30m 0.25mm, 0.25m G16 stationary phase). Limits of residual
solvents are based upon the International Conference on Harmo-
nisation of Technical Requirements for Registration of Pharma-
ceuticals for Human Use guidelines.
Radionuclidic identity
Radionuclidic identity is conﬁrmed by measuring the half-life of
radiopharmaceutical doses and comparing it with the known
half-life of carbon-11 (20.8min). Activities are measured using a
Capintec CRCW-15R Radioisotope Dose Calibrator, and half-life
is calculated using equation 1. Calculated half-life must be
18.4–22.4min.
T1=2 ¼ ln2 TimeDifference= ln endingactivity=startingactivityð Þð Þð Þ
(1)
Sterile ﬁlter integrity (Bubble Point) test
Sterile ﬁlters from doses (with needle still attached) are connected
to a nitrogen supply via a regulator. The needle is then
submerged in water, and the nitrogen pressure is gradually
increased. If the pressure is raised above the ﬁlter acceptance
pressure (typically 40psi) without seeing a stream of bubbles,
the ﬁlter is considered intact.
Bacterial endotoxins
Endotoxin content in radiopharmaceutical doses is analyzed
using a Charles River Laboratories EndoSafeW Portable Testing
System and according to USP. Doses must contain <175 endo-
toxin units.
Sterility
Culture tubes of ﬂuid thioglycolate media (FTM) and tryptic soy
broth (TSB) are inoculated with samples of [11C]-labeled radio-
pharmaceutical doses and incubated (along with positive and
negative controls) for 14 days. FTM is used to test for anaerobes,
aerobes, and microaerophiles, whereas TSB is used to test for
non-fastidious and fastidious microorganisms. Culture tubes are
visually inspected on the 3rd, 7th, and 14th days of the test
period and compared with the positive and negative standards.
Positive standards must show growth (turbidity) on the plates
and dose/negative controls must have no culture growth after
14 days to be indicative of sterility.
Conclusions
In conclusion, the Tracerlab FXC-Pro has proven to be an efﬁcient
automated synthesis module for preparation of many carbon-11
labeled radiopharmaceuticals in our laboratory. The results
disclosed herein demonstrate that through simple modiﬁcation
of the ‘standard’ synthesis module conﬁguration, the system
can be conﬁgured (and re-conﬁgured) in a straightforward
manner to allow production of clinical doses of many different
radiopharmaceuticals. The production of the radiopharmaceuti-
cals discussed herein demonstrates that numerous differentwww.jlcr.orght © 2011 John Wiley & Sons, Ltd.
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836carbon-11 radiolabeling strategies can be adapted for use with
the Tracerlab FXC-Pro. Each synthesis has been fully automated,
and all radiopharmaceutical doses for clinical use meet or exceed
established QC criteria.
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